Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in South Dakota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (189 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 5 | 241 | 23% |
| 2020 | 4 | 227 | 25% |
| 2021 | 6 | 214 | 28% |
| 2022 | 8 | 237 | 32% |
| 2023 | 6 | 252 | 36% |
| 2024 | 8 | 255 | 39% |
| 2025 from claims | – | 314 256–370 | 41% |
| 2026 forecast | – | 348 276–441 | 39% |
| 2027 forecast | – | 370 278–494 | 39% |
| 2028 forecast | – | 393 283–549 | 39% |
| 2029 forecast | – | 418 290–606 | 40% |
| 2030 forecast | – | 444 297–668 | 40% |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in South Dakota; 6 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 22% inpatient hospital, 78% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~350 | ~72 | ~280 |
| 2027 · ~370 | ~74 | ~300 |
| 2028 · ~390 | ~77 | ~320 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 20% (22% in 2025), hospital outpatient about 80% (78% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 19 | 1,439−1.6%/yr | −1.6%/yr | 1.4 | 0% | 1,680 in 2030+2.6%/yr |
| Illinois | 22 | 1,307−0.8%/yr | −0.8%/yr | 1.0 | 0% | 1,520 in 2030+2.6%/yr |
| Indiana | 17 | 840−1.2%/yr | −1.2%/yr | 1.3 | 0% | 1,260 in 2030+7%/yr |
| Michigan | 10 | 775−4.3%/yr | −4.3%/yr | 1.0 | 0% | 990 in 2030+4.2%/yr |
| Minnesota | 10 | 677+0.4%/yr | +0.4%/yr | 1.7 | 0% | 1,230 in 2030+10%/yr |
| Missouri | 11 | 665−3.3%/yr | −3.3%/yr | 1.2 | 0% | 780 in 2030+2.7%/yr |
| Wisconsin | 15 | 626−2%/yr | −2%/yr | 1.2 | 0% | 830 in 2030+4.8%/yr |
| Kansas | 10 | 475−3.5%/yr | −3.5%/yr | 1.2 | 0% | 560 in 2030+2.9%/yr |
| Iowa | 8 | 407+2%/yr | +2%/yr | 1.0 | 0% | 430 in 2030+0.9%/yr |
| Nebraska | 9 | 365−2.1%/yr | −2.1%/yr | 1.5 | 0% | 390 in 2030+1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 12 | 636+8.3%/yr | +8.3%/yr | 4.91.1× | 4% | 580 in 2030−1.6%/yr |
| Kidney stone management | 18 | 626+2.5%/yr | +2.5%/yr | 4.90.9× | 0% | 840 in 2030+5%/yr |
| Incontinence, prolapse & sacral neuromodulation | 4 | 423+0.9%/yr | +0.9%/yr | 3.21.5× | 0% | 560 in 2030+4.9%/yr |
| Hysterectomy, hysteroscopy & ablation | 2 | 327−0.7%/yr | −0.7%/yr | 2.70.9× | 0% | 360 in 2030+1.8%/yr |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in South Dakota · Every state · Compare with Ohio
Intuitive Surgical leads with 100% of company spending on these surgeons in 2025, level with 2024.
In 2025, 2 companies reported engagement with South Dakota’s surgeons worth $37K in consulting, speaking, meals and travel tied to these products, about $4,564 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.